Volume | 130,259 |
|
|||||
News | - | ||||||
Day High | 1.45 | Low High |
|||||
Day Low | 1.40 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.45 | 1.40 | 1.45 | 1.405 | 1.46 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
332 | 130,259 | US$ 1.42 | US$ 185,279 | - | 0.99 - 1.89 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 1,206 | US$ 1.405 | USD |
Spero Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
75.42M | 53.87M | - | 103.78M | 22.81M | 0.42 | 3.31 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spero Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.43 | 1.46 | 1.40 | 1.44 | 109,085 | -0.025 | -1.75% |
1 Month | 1.72 | 1.72 | 1.40 | 1.52 | 138,674 | -0.315 | -18.31% |
3 Months | 1.71 | 1.84 | 1.37 | 1.63 | 215,631 | -0.305 | -17.84% |
6 Months | 1.28 | 1.89 | 1.2001 | 1.59 | 247,368 | 0.125 | 9.77% |
1 Year | 1.80 | 1.89 | 0.99 | 1.48 | 256,462 | -0.395 | -21.94% |
3 Years | 14.31 | 19.87 | 0.6801 | 2.30 | 961,316 | -12.91 | -90.18% |
5 Years | 10.39 | 23.639 | 0.6801 | 3.53 | 643,930 | -8.99 | -86.48% |
Spero Therapeutics Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |